{"analyses":[{"ciLowerLimit":"0.38","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.63","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","paramType":"Hazard Ratio (HR)","paramValue":"0.49","statisticalMethod":"Regression, Cox"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.52","upperLimit":"7.36","value":"5.82"},{"groupId":"OG001","lowerLimit":"2.2","upperLimit":"3.65","value":"3.52"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"256"},{"groupId":"OG001","value":"131"}],"units":"Participants"}],"description":"The time from randomisation until the date of objective radiological disease progression (by RECIST 1.1 and Prostate Cancer Working Group 3 (PGWG-3)) or death (by any cause in the absence of progression) regardless of whether the patient withdrew from randomised therapy or received another anti-cancer therapy prior to progression.","dispersionType":"95% Confidence Interval","groups":[{"description":"2x150mg film-coated tablets","id":"OG000","title":"Cohort A Olaparib 300mg bd"},{"description":"either enzalutamide capsules (160 mg od) or abiraterone acetate tablets (1,000 mg od with 5 mg bid prednisone)","id":"OG001","title":"Cohort A Investigators Choice of NHA"}],"paramType":"MEDIAN","populationDescription":"Full Analysis Set","reportingStatus":"POSTED","timeFrame":"Tumor assessments every 8 weeks from randomisation until radiographic progression assessed by BICR (median duration of treatment of 7 and 4 months for Olaparib and Investigators Choice of NHA respectively).","title":"Radiological Progression Free Survival (rPFS) by Blinded Independent Central Review (BICR) - Cohort A+B","type":"SECONDARY","unitOfMeasure":"Months"}